Cathepsin S

Cathepsin S is a protein that in humans is encoded by the CTSS gene.[5] Transcript variants utilizing alternative polyadenylation signals exist for this gene.[5]

CTSS
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCTSS, entrez:1520, cathepsin S
External IDsOMIM: 116845 MGI: 107341 HomoloGene: 20867 GeneCards: CTSS
Orthologs
SpeciesHumanMouse
Entrez

1520

13040

Ensembl

ENSG00000163131

ENSMUSG00000038642

UniProt

P25774

O70370

RefSeq (mRNA)

NM_004079
NM_001199739

NM_001267695
NM_021281

RefSeq (protein)

NP_001186668
NP_004070

NP_001254624
NP_067256

Location (UCSC)Chr 1: 150.73 – 150.77 MbChr 3: 95.43 – 95.46 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Cathepsin S is a member of the peptidase C1 family of cysteine cathepsins,[6] a lysosomal cysteine protease that may participate in the degradation of antigenic proteins to peptides for presentation to the MHC class II.[7][8] Cathepsin S can function as an elastase over a broad pH range in alveolar macrophages.[9][10]

Function

Cathepsin S is a lysosomal enzyme that belongs to the papain-like protease of cysteine proteases.[11][12] While a role in antigen presentation has long been recognized,[13][14] it is now understood that cathepsin S has a role in itch and pain, or nociception.[15] The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family.[16]

Cathepsin S is expressed by antigen presenting cells including macrophages, B-lymphocytes, dendritic cells and microglia.[17][18] Cathepsin S is expressed by some epithelial cells.[19] Its expression is markedly increased in human keratinocytes following stimulation with interferon-gamma and its expression is elevated in psoriatic keratinocytes due to stimulation by proinflammatory factors.[20] In contrast, cortical thymic epithelial cells do not express cathepsin S.[21][22]

While pH optima of many lysosomal proteases are acidic,[23][24][25] cathepsin S is an exception. This enzyme remains catalytically active under the neutral pH and has pH optimum between the pH values 5.0 and 7.5.[26][27] Many lysosomal proteases are trapped inside the lysosome due to a problem with their stability. In contrast, cathepsin S remains stable and has a physiological role outside the lysosome.[28][29] Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides,[30] proinflammatory cytokines[31] and neutrophils.[32] In vitro, cathepsin S retains some enzyme activity in the presence of 3M urea.[33] Cathepsin S is produced as a zymogen and is activated by processing.[34]

The activity of cathepsin S is tightly regulated by its endogenous inhibitor, cystatin C, which also has a role in antigen presentation.[35][36] Cystatin A and B have a lower activity compared to cystatin C.[37]

The active cleavage sites -(-Val-Val-Arg-)- of cathepsin S are supposed to have at least two amino acids surrounding it from each side.[38]

While lysosomal proteases terminally degrade proteins in lysosomes, cathepsin S has own distinctive physiological role.[39]

Role in antigen presentation

This enzyme has a critical role in antigen presentation. Major histocompatibility complex class II molecules interact with small peptide fragments for presentation on the surface of antigen-presenting immune cells. Cathepsin S participates in the degradation of the invariant or Ii chain that prevents loading the antigen into the complex. This degradation occurs in the lysosome. Chronologically, action of cathepsin S follows two cleavages performed by aspartyl proteases. Cathepsin S cleaves the remaining fragment of Ii (IiP1) and leaves a small part of Ii known as CLIP which stays directly associated with the complex.

Proteolytic degradation of Ii is important since it facilitates dissociation of CLIP from MHC II and then, complex can load the selected antigen. After loading the antigen, MHC II molecule moves to the cell surface. Thus, we can speculate that overexpression of cathepsin S may lead to premature degradation of Ii, occasional loading of MHC II and an autoimmune attack. Contrary, inhibition of cathepsin S will lead to a delay in degradation of Ii and loading the antigen into MHC II as well as inappropriate presence of uncleaved Li-fragments in MHC II on the cell surface. It will impair and weaken the immune response. For instance, this kind of MHC II will not be very efficient to induce proliferation of T-cells.

In macrophages, cathepsin S can be replaced by cathepsin F.

Role in degradation of ECM

Secreted cathepsin S cleaves some extracellular matrix (ECM) proteins. Cathepsin S may be considered the most potent elastase known. The list of proposed cathepsin S substrates includes laminin, fibronectin elastin, osteocalcin and some collagens. It also cleaves chondroitin sulfate, heparan sulfate and proteoglycans of the basal membrane. Cathepsin S plays an active role in blood vessels permeability and angiogenesis due to its elastolytic and collagenolytic activities. For instance, cleavage of laminin-5 by cathepsin S leads to generation of proangiogenic peptides. The expression of cathepsin S can be triggered by proinflammatory factors secreted by tumor cells.

In tumorogenesis, cathepsin S promotes a tumor growth.

Role in cytokine regulation

Cathepsin S expression and activity has also been shown to be upregulated in the skin of psoriasis patients. Whether it has a definitive role in causing the pathology of psoriasis is as yet unknown, however in the same study it was shown to specially cleave and activate the psoriasis-associated proinflammatory cytokine IL-36γ[40]

Nociception

Cathepsin S has a role in nociception, including itch and gastrointestinal pain. The mechanism by which cathepsin S leads to itch and pain is consistent with the capacity of this cysteine protease to activate protease-activated receptors 2 and 4.[41][16]

Cathepsin S inhibitors

Synthetic inhibitors of cathepsin S participated in numerous preclinical studies for the immune disorders including rheumatoid arthritis. Currently, at least one of them participates in a clinical trial for psoriasis. LHVS (morpholinurea-leucine-homophenylalanine-vinylsulfone-phenyl) is the most extensively studied synthetic inhibitor of cathepsin S. IC50 of LHVS is about 5 nM. Inhibition of cathepsin S by LHVS has shown to be neuroprotective after traumatic brain injury.[42] The list of commercial inhibitors also includes paecilopeptin (acetyl-Leu-Val-CHO) and some others.

Clinical significance

Cathepsin S has been shown to be a significant prognostic factor for patients with type IV astrocytomas (glioblastoma multiforme), and its inhibition has shown improvement in survival time by mean average 5 months. This is because the cysteine enzyme can no longer act together with other proteases to break up the brain extracellular matrix. So the spread of the tumor is halted. Scientists have just announced that this enzyme predicts death, as it has been shown to be associated with both heart disease and cancer. (citation?)

See also

References
  1. GRCh38: Ensembl release 89: ENSG00000163131 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000038642 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. "Entrez Gene: CTSS cathepsin S".
  6. Wang GH, He SW, Du X, Xie B, Gu QQ, Zhang M, Hu YH (October 2019). "Characterization, expression, enzymatic activity, and functional identification of cathepsin S from black rockfish Sebastes schlegelii". Fish & Shellfish Immunology. 93: 623–630. doi:10.1016/j.fsi.2019.08.012. PMID 31400512. S2CID 199527780.
  7. Cheng XW, Zhang J, Song H, Yang G, Qin XZ, Guan LK, et al. (January 2008). "[Association between lysosomal cysteine protease cathepsin's activation and left ventricular function and remodeling in hypertensive heart failure rats]". Zhonghua Xin Xue Guan Bing Za Zhi. 36 (1): 51–56. PMID 19099930.
  8. Chen SJ, Chen LH, Yeh YM, Lin CK, Lin PC, Huang HW, et al. (2021). "Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy". Theranostics. 11 (10): 4672–4687. doi:10.7150/thno.54793. PMC 7978314. PMID 33754020.
  9. Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA (April 1992). "Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease". The Journal of Biological Chemistry. 267 (11): 7258–7262. doi:10.1016/S0021-9258(18)42513-6. PMID 1373132.
  10. Tanaka H, Yamaguchi E, Asai N, Yokoi T, Nishimura M, Nakao H, et al. (2019). "Cathepsin S, a new serum biomarker of sarcoidosis discovered by transcriptome analysis of alveolar macrophages". Sarcoidosis, Vasculitis, and Diffuse Lung Diseases. 36 (2): 141–147. doi:10.36141/svdld.v36i2.7620. PMC 7247107. PMID 32476947.
  11. Brömme D, Bonneau PR, Lachance P, Storer AC (December 1994). "Engineering the S2 subsite specificity of human cathepsin S to a cathepsin L- and cathepsin B-like specificity". The Journal of Biological Chemistry. 269 (48): 30238–30242. doi:10.1016/S0021-9258(18)43803-3. PMID 7982933.
  12. Turk B, Turk V, Turk D (March 1997). "Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors". Biological Chemistry. 378 (3–4): 141–150. PMID 9165064.
  13. Liu W, Spero DM (July 2004). "Cysteine protease cathepsin S as a key step in antigen presentation". Drug News & Perspectives. 17 (6): 357–363. doi:10.1358/dnp.2004.17.6.829027. PMID 15334187.
  14. Baranov MV, Bianchi F, Schirmacher A, van Aart MA, Maassen S, Muntjewerff EM, et al. (January 2019). "The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II Antigen Presentation". iScience. 11: 160–177. Bibcode:2019iSci...11..160B. doi:10.1016/j.isci.2018.12.015. PMC 6319320. PMID 30612035.
  15. Tu NH, Inoue K, Chen E, Anderson BM, Sawicki CM, Scheff NN, et al. (September 2021). "Cathepsin S Evokes PAR2-Dependent Pain in Oral Squamous Cell Carcinoma Patients and Preclinical Mouse Models". Cancers. 13 (18): 4697. doi:10.3390/cancers13184697. PMC 8466361. PMID 34572924.
  16. Reddy VB, Sun S, Azimi E, Elmariah SB, Dong X, Lerner EA (July 2015). "Redefining the concept of protease-activated receptors: cathepsin S evokes itch via activation of Mrgprs". Nature Communications. 6: 7864. Bibcode:2015NatCo...6.7864R. doi:10.1038/ncomms8864. PMC 4520244. PMID 26216096.
  17. Reich M, Zou F, Sieńczyk M, Oleksyszyn J, Boehm BO, Burster T (2011). "Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells". Cellular Immunology. 269 (2): 96–103. doi:10.1016/j.cellimm.2011.03.012. PMID 21543057.
  18. Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, et al. (February 2015). "Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming" (PDF). Annals of the Rheumatic Diseases. 74 (2): 452–463. doi:10.1136/annrheumdis-2013-203717. PMID 24300027. S2CID 22126353.
  19. da Costa AC, Santa-Cruz F, Mattos LA, Rêgo Aquino MA, Martins CR, Bandeira Ferraz ÁA, Figueiredo JL (February 2020). "Cathepsin S as a target in gastric cancer". Molecular and Clinical Oncology. 12 (2): 99–103. doi:10.3892/mco.2019.1958. PMC 6951222. PMID 31929878.
  20. Schönefuss A, Wendt W, Schattling B, Schulten R, Hoffmann K, Stuecker M, et al. (August 2010). "Upregulation of cathepsin S in psoriatic keratinocytes". Experimental Dermatology. 19 (8): e80–e88. doi:10.1111/j.1600-0625.2009.00990.x. PMID 19849712. S2CID 31731844.
  21. Kiuchi S, Tomaru U, Ishizu A, Imagawa M, Kiuchi T, Iwasaki S, et al. (February 2017). "Expression of cathepsins V and S in thymic epithelial tumors". Human Pathology. 60: 66–74. doi:10.1016/j.humpath.2016.09.027. PMID 27771373.
  22. Beers C, Burich A, Kleijmeer MJ, Griffith JM, Wong P, Rudensky AY (February 2005). "Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo". Journal of Immunology. 174 (3): 1205–1212. doi:10.4049/jimmunol.174.3.1205. PMID 15661874. S2CID 30821915.
  23. Wilkinson RD, Williams R, Scott CJ, Burden RE (August 2015). "Cathepsin S: therapeutic, diagnostic, and prognostic potential". Biological Chemistry. 396 (8): 867–882. doi:10.1515/hsz-2015-0114. PMID 25872877. S2CID 17582321.
  24. Liuzzo JP, Petanceska SS, Devi LA (May 1999). "Neurotrophic factors regulate cathepsin S in macrophages and microglia: A role in the degradation of myelin basic protein and amyloid beta peptide". Molecular Medicine. 5 (5): 334–343. doi:10.1007/BF03402069. PMC 2230424. PMID 10390549.
  25. Sena BF, Figueiredo JL, Aikawa E (2017). "Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease". Frontiers in Cardiovascular Medicine. 4: 88. doi:10.3389/fcvm.2017.00088. PMC 5770806. PMID 29379789.
  26. Kim NY, Ahn SJ, Lee AR, Seo JS, Kim MS, Kim JK, et al. (November 2010). "Cloning, expression analysis and enzymatic characterization of cathepsin S from olive flounder (Paralichthys olivaceus)". Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology. 157 (3): 238–247. doi:10.1016/j.cbpb.2010.06.008. PMID 20601061.
  27. Brömme D, Bonneau PR, Lachance P, Wiederanders B, Kirschke H, Peters C, et al. (March 1993). "Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme". The Journal of Biological Chemistry. 268 (7): 4832–4838. doi:10.1016/S0021-9258(18)53472-4. PMID 8444861.
  28. Karimkhanloo H, Keenan SN, Sun EW, Wattchow DA, Keating DJ, Montgomery MK, Watt MJ (February 2021). "Circulating cathepsin S improves glycaemic control in mice". The Journal of Endocrinology. 248 (2): 167–179. doi:10.1530/JOE-20-0408. PMID 33289685. S2CID 227951644.
  29. Bibli SI, Hu J, Sigala F, Wittig I, Heidler J, Zukunft S, et al. (January 2019). "Cystathionine γ Lyase Sulfhydrates the RNA Binding Protein Human Antigen R to Preserve Endothelial Cell Function and Delay Atherogenesis". Circulation. 139 (1): 101–114. doi:10.1161/CIRCULATIONAHA.118.034757. PMID 29970364. S2CID 49652298.
  30. Janga H, Cassidy L, Wang F, Spengler D, Oestern-Fitschen S, Krause MF, et al. (February 2018). "Site-specific and endothelial-mediated dysfunction of the alveolar-capillary barrier in response to lipopolysaccharides". Journal of Cellular and Molecular Medicine. 22 (2): 982–998. doi:10.1111/jcmm.13421. PMC 5783864. PMID 29210175.
  31. Ainscough JS, Macleod T, McGonagle D, Brakefield R, Baron JM, Alase A, et al. (March 2017). "Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ". Proceedings of the National Academy of Sciences of the United States of America. 114 (13): E2748–E2757. Bibcode:2017PNAS..114E2748A. doi:10.1073/pnas.1620954114. PMC 5380102. PMID 28289191.
  32. Wang H, Jiang H, Cheng XW (2022). "Cathepsin S are involved in human carotid atherosclerotic disease progression, mainly by mediating phagosomes: bioinformatics and in vivo and vitro experiments". PeerJ. 10: e12846. doi:10.7717/peerj.12846. PMC 8833225. PMID 35186462.
  33. Flynn CM, Garbers Y, Düsterhöft S, Wichert R, Lokau J, Lehmann CH, et al. (December 2020). "Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro". Scientific Reports. 10 (1): 21612. Bibcode:2020NatSR..1021612F. doi:10.1038/s41598-020-77884-4. PMC 7730449. PMID 33303781.
  34. Wiederanders B (2000). "The function of propeptide domains of cysteine proteinases". Advances in Experimental Medicine and Biology. 477: 261–270. doi:10.1007/0-306-46826-3_28. ISBN 0-306-46383-0. PMID 10849753.
  35. Paraoan L, Gray D, Hiscott P, Garcia-Finana M, Lane B, Damato B, Grierson I (January 2009). "Cathepsin S and its inhibitor cystatin C: imbalance in uveal melanoma". Frontiers in Bioscience. 14 (7): 2504–2513. doi:10.2741/3393. PMID 19273215.
  36. Zhang W, Zi M, Sun L, Wang F, Chen S, Zhao Y, et al. (November 2019). "Cystatin C regulates major histocompatibility complex-II-peptide presentation and extracellular signal-regulated kinase-dependent polarizing cytokine production by bone marrow-derived dendritic cells". Immunology and Cell Biology. 97 (10): 916–930. doi:10.1111/imcb.12290. hdl:11343/286503. PMID 31513306. S2CID 213168319.
  37. Bangsuwan P, Hirunwidchayarat W, Jirawechwongsakul P, Talungchit S, Taebunpakul P (September 2021). "Expression of Cathepsin B and Cystatin A in Oral Lichen Planus". Journal of International Society of Preventive & Community Dentistry. 11 (5): 566–573. doi:10.4103/jispcd.JISPCD_97_21 (inactive 31 December 2022). PMC 8533036. PMID 34760802.{{cite journal}}: CS1 maint: DOI inactive as of December 2022 (link)
  38. Fu Q, Zhao S, Yang N, Tian M, Cai X, Zhang L, et al. (July 2020). "Genome-wide identification, expression signature and immune functional analysis of two cathepsin S (CTSS) genes in turbot (Scophthalmus maximus L.)". Fish & Shellfish Immunology. 102: 243–256. doi:10.1016/j.fsi.2020.04.028. PMID 32315741. S2CID 216074706.
  39. Sage J, Mallèvre F, Barbarin-Costes F, Samsonov SA, Gehrcke JP, Pisabarro MT, et al. (September 2013). "Binding of chondroitin 4-sulfate to cathepsin S regulates its enzymatic activity". Biochemistry. 52 (37): 6487–6498. doi:10.1021/bi400925g. PMID 23968158.
  40. Ainscough JS, Macleod T, McGonagle D, Brakefield R, Baron JM, Alase A, et al. (March 2017). "Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ". Proceedings of the National Academy of Sciences of the United States of America. 114 (13): E2748–E2757. Bibcode:2017PNAS..114E2748A. doi:10.1073/pnas.1620954114. PMC 5380102. PMID 28289191.
  41. Elmariah SB, Reddy VB, Lerner EA (June 25, 2014). "Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist". PLOS ONE. 9 (6): e99702. Bibcode:2014PLoSO...999702E. doi:10.1371/journal.pone.0099702. PMC 4070910. PMID 24964046.
  42. Xu J, Wang H, Ding K, Lu X, Li T, Wang J, et al. (Oct 24, 2013). "Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice". Mediators of Inflammation. 2013 (2013): 187873. doi:10.1155/2013/187873. PMC 3824312. PMID 24282339.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.